Clinical Trial Update: Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) [Phase 3]

View source ↗

Summary

A Phase 3 study compares 12 months versus 36 months of imatinib therapy in patients with gastrointestinal stromal tumor (GIST) to determine the optimal duration…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Sarcoma

Drugs mentioned

• Imatinib (imatinib)

Snippet

Sponsor: Scandinavian Sarcoma Group | Conditions: Sarcoma | Phase 3 | Status: COMPLETED